ReviewReviews in cardiovascular medicine2025
The Beneficial Effects of Glucagon-Like Peptide-1 Agonists on Blood Pressure: A Comprehensive Review.
Review in Reviews in cardiovascular medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 1 synthesis or guideline pooled it.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hypertension is a prominent cardiovascular risk factor, especially among patients with diabetes and obesity. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are a class of drugs originally developed to improve glycemic control in patients with diabetes; however, these agonists have subsequently demonstrated additional cardioprotective effects, including modest reductions in blood pressure (BP). This literature review examines the various mechanisms through which GLP-1 RAs reduce BP, including weight loss, improved endothelial function, and renal sodium management. While GLP-1 RAs are less potent in BP reduction compared to conventional antihypertensive agents, the broader metabolic benefits of these agonists make this class of drug a valuable adjunct in managing hypertension, particularly in patients with metabolic syndrome. Nonetheless, further studies are needed to explore the long-term effects of BP and optimize patient selection for maximal cardiovascular benefit.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.